open access

Vol 17, No 2 (2012)
Published online: 2012-03-01
Submitted: 2011-11-28
Get Citation

Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value > 40ng/ml

Jiri Kubeš, Cvek Jakub, Vondráček Vladimir, Dvořák Jan, Argalacsová Sona, Navrátil Matej, Buřil Jan
DOI: 10.1016/j.rpor.2012.01.006
·
Rep Pract Oncol Radiother 2012;17(2):79-84.

open access

Vol 17, No 2 (2012)
Published online: 2012-03-01
Submitted: 2011-11-28

Abstract

Aim

To evaluate the outcome of prostate cancer patients with initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml.

Background

The outcome of prostate cancer patients with very high initial PSA value is not known and patients are frequently treated with palliative intent. We analyzed the outcome of radical combined hormonal treatment and radiotherapy in prostate cancer patients with initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml.

Methods

Between January 2003 and December 2007 we treated, with curative intent, 56 patients with non-metastatic prostate cancer and initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml. The treatment consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68–78[[ce:hsp sp="0.25"/]]Gy, conformal technique) and an optional two-year adjuvant hormonal treatment.

Results

The median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiotherapy dose did not significantly influence the outcome. Late genitourinal and gastrointestinal toxicity was acceptable.

Conclusion

Radical treatment in combination with hormonal treatment and radiotherapy can be recommended for this subgroup of prostate cancer patients with good performance status and life expectancy.

Abstract

Aim

To evaluate the outcome of prostate cancer patients with initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml.

Background

The outcome of prostate cancer patients with very high initial PSA value is not known and patients are frequently treated with palliative intent. We analyzed the outcome of radical combined hormonal treatment and radiotherapy in prostate cancer patients with initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml.

Methods

Between January 2003 and December 2007 we treated, with curative intent, 56 patients with non-metastatic prostate cancer and initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml. The treatment consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68–78[[ce:hsp sp="0.25"/]]Gy, conformal technique) and an optional two-year adjuvant hormonal treatment.

Results

The median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiotherapy dose did not significantly influence the outcome. Late genitourinal and gastrointestinal toxicity was acceptable.

Conclusion

Radical treatment in combination with hormonal treatment and radiotherapy can be recommended for this subgroup of prostate cancer patients with good performance status and life expectancy.

Get Citation

Keywords

Prostate cancer; PSA; High risk; Radiotherapy

About this article
Title

Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40ng/ml

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 17, No 2 (2012)

Pages

79-84

Published online

2012-03-01

DOI

10.1016/j.rpor.2012.01.006

Bibliographic record

Rep Pract Oncol Radiother 2012;17(2):79-84.

Keywords

Prostate cancer
PSA
High risk
Radiotherapy

Authors

Jiri Kubeš
Cvek Jakub
Vondráček Vladimir
Dvořák Jan
Argalacsová Sona
Navrátil Matej
Buřil Jan

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl